Core Viewpoint - Shanghai Haohai Biological Technology Co., Ltd. (Haohai) has announced the acquisition of the remaining 20% stake in Shenzhen New Industry Ophthalmology Technology Co., Ltd. for 74 million yuan, aiming to enhance its market competitiveness in ophthalmic products amid declining performance in its core business [1][3]. Group 1: Acquisition Details - Haohai's wholly-owned subsidiary, Shanghai Haohai Pharmaceutical Technology, will acquire the remaining 20% stake in New Industry Ophthalmology, completing a nine-year strategic layout that began with a 60% stake acquisition in November 2016 [1][2]. - New Industry Ophthalmology specializes in manufacturing and selling orthokeratology lenses and intraocular lenses, as well as distributing various imported ophthalmic products in mainland China [1]. Group 2: Financial Performance - As of December 31, 2024, New Industry Ophthalmology's total assets were valued at 250 million yuan, with projected after-tax profits of 32.735 million yuan for 2023, 22.0062 million yuan for 2024, and 16.1877 million yuan for the first half of 2025 [2]. - The acquisition is expected to improve management and operational efficiency, thereby enhancing the competitiveness of Haohai's ophthalmic products [2]. Group 3: Business Challenges - Haohai's overall performance has been under pressure, with a significant slowdown in revenue growth. In 2024, the company reported revenue of 2.698 billion yuan, reflecting a mere 1.64% year-on-year increase, a stark contrast to the double-digit growth seen from 2021 to 2023 [3]. - The company's three main business segments, including ophthalmology, experienced revenue declines in the first half of 2025, with ophthalmic products down by 18.61% [4]. Group 4: Strategic Response - The acquisition of New Industry Ophthalmology is viewed as a strategic move to address declining performance, with Haohai planning to enhance its product offerings and market presence in the ophthalmic sector [6]. - The company aims to promote its self-developed orthokeratology lenses and expand its product line to improve market share, despite ongoing challenges from price reductions due to national and provincial procurement policies [5][6].

Core Viewpoint - Haohai Biological Technology (06826.HK) announced the acquisition of the remaining 20% equity in Shenzhen New Industry Ophthalmic New Technology Co., Ltd. for RMB 74 million, aiming to enhance its market competitiveness in the ophthalmic high-value consumables sector [1]. Group 1: Acquisition Details - The acquisition agreement was signed between Shanghai Haohai Pharmaceutical Technology Development Co., Ltd. (a wholly-owned subsidiary of the company) and the sellers, which include Zhang Jinsong, Shenzhen Jiusi, and Shenzhen Bainai [1]. - Upon completion of the acquisition, the company will hold 100% equity in the target company, which specializes in the manufacturing and sales of orthokeratology lenses and intraocular lenses, as well as the distribution of various imported ophthalmic products in mainland China [1]. Group 2: Strategic Importance - The company has progressively entered the ophthalmic high-value consumables market since acquiring 60% and 20% stakes in the target company in November 2016 and February 2023, respectively [1]. - The target company has become a key subsidiary, contributing to the company's position as a leading manufacturer of intraocular lenses in China [1]. - The acquisition is expected to improve management and operational efficiency of the target company, thereby enhancing the overall competitiveness of the company's ophthalmic products [1].

Core Viewpoint - Haohai Biological Technology (06826) announced the acquisition of the remaining 20% equity in Shenzhen New Industry Ophthalmic Technology Co., Ltd. for RMB 74 million, aiming to enhance its market position in the ophthalmic high-value consumables sector [1] Group 1: Acquisition Details - The acquisition agreement was signed on November 7, 2025, between Haohai's wholly-owned subsidiary Shanghai Haohai Pharmaceutical Technology and the sellers [1] - After the completion of this acquisition, the company will hold 100% equity in the target company [1] Group 2: Target Company Overview - The target company specializes in the manufacturing and sales of orthokeratology lenses and artificial lenses, as well as the distribution of various imported ophthalmic products in mainland China [1] - The company has been progressively entering the ophthalmic high-value consumables market since acquiring 60% and 20% stakes in 2016 and 2023, respectively [1] Group 3: Strategic Importance - The acquisition is expected to improve the management and operational efficiency of the target company, thereby enhancing the competitiveness of the company's ophthalmic products in the market [1] - The board believes that this acquisition aligns with the company's development needs and overall business strategy [1]

Core Viewpoint - The company, Haohai Biological Technology, is acquiring the remaining 20% equity of Shenzhen New Industry Ophthalmic New Technology Co., Ltd. for RMB 74 million, aiming to enhance its management and operational efficiency in the ophthalmic high-value consumables sector [1] Group 1: Acquisition Details - The acquisition agreement involves Haohai's wholly-owned subsidiary, Shanghai Haohai Pharmaceutical Technology, as the acquirer and includes the transfer of equity from Mr. Zhang, Shenzhen Jiusi, and Shenzhen Baina [1] - Upon completion of the acquisition, the company will hold 100% equity in the target company, which specializes in the manufacturing and sales of orthokeratology lenses and artificial lenses [1] Group 2: Strategic Importance - The target company has been a significant subsidiary since Haohai acquired 60% and 20% stakes in November 2016 and February 2023, respectively [1] - The acquisition aligns with the company's strategic goal to strengthen its position as a leading manufacturer of artificial lenses in China and improve market competitiveness in ophthalmic products [1]

Core Viewpoint - Haohai Biological Technology (06826.HK) announced the acquisition of the remaining 20% equity in Shenzhen New Industry Ophthalmic New Technology Co., Ltd. for RMB 74 million, aiming to enhance its management and operational efficiency in the ophthalmic high-value consumables sector [1] Group 1: Acquisition Details - The acquisition agreement was signed between Shanghai Haohai Pharmaceutical Technology Development Co., Ltd. (a wholly-owned subsidiary of the company) and the sellers (Zhang Jinsong, Shenzhen Jiusi, and Shenzhen Bainai) [1] - Upon completion of the acquisition, the company will hold 100% equity in the target company [1] Group 2: Target Company Overview - The target company is a limited liability company established in China, primarily engaged in the manufacturing and sales of orthokeratology lenses and intraocular lens products [1] - It also distributes various imported ophthalmic products, including intraocular lenses, ophthalmic viscoelastic devices, and sodium hyaluronate gel for glaucoma surgery in mainland China [1] Group 3: Strategic Importance - The company has progressively entered the ophthalmic high-value consumables market since acquiring 60% and 20% stakes in the target company in November 2016 and February 2023, respectively [1] - The target company has become one of the main subsidiaries of the group, contributing to its position as a leading manufacturer of intraocular lens products in China [1] - The board believes that the acquisition aligns with the company's development needs and overall business planning, enhancing market competitiveness in ophthalmic products [1]